Latest Conference Articles

Carol Burke, MD, FACG, FASGE, talks about her phase-3 placebo-controlled trial of Celecoxib in pediatric subjects with familial adenomatous polyposis (FAP) at the 2014 ACG Annual Meeting in Philadelphia, PA.

To ensure that anaphylaxis episodes are treated in a timely and effective manner, action plans should be developed and distributed to patients, family and other caregivers, and schools.

A detailed presentation at AAP 2014 covered recent hot topics in antibiotic development, microbial resistance, pneumonia treatment, fluoroquinolone safety, and the impact of antibiotic use on the gut microbiome.

Atopic dermatitis is the most common inflammatory pediatric skin disorder, with reported incidences ranging from 10% to 20%. The principles of effect care include fixing the skin barrier, short-circuiting inflammation, decreasing itching, treating infections, and striving for prevention by addressing the triggers.

Jeff Duchin, MD, of the Seattle and King County Departments of Public Health, discusses enterovirus and the relationship with treatment during cold and flu season.

Results from a study of herpes zoster incidence following periods of acute stress in a large cohort of patients suggest the conventional wisdom on this subject may be wrong.

Although methadone accounts for only 2% of opioid prescriptions, it caused nearly one in 3 prescription opioid overdose deaths in 2012, a 6-fold increase from 2009, according to the CDC.

Because there is no objective test for pain, and because each patient's experience of his or her painful condition is subjective and unique, physicians who treat these patients must process a variety of symptoms, signs, and cues to determine whether they can trust their patient's narrative.

A new pill could be the next tool in a patient's fight to lose weight, according to a recent study.

Researchers find that the ratio of total cholesterol to HDL is a significant predictor for CVD in type 1 diabetes patients who are not using lipid-lowering drugs, and that the ratio of total cholesterol to HDL is a more reliable marker for risk when considering primary prevention.

Coping strategies based on enhanced mindfulness and a greater sense of agency can help patients improve their quality of life.

Results from two studies show that treatment with the novel kinase inhibitor nintedanib significantly slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF). However, only one study showed nintedanib had any effect on slowing deterioration in quality of life or reducing the risk of a first acute exacerbation compared with placebo.

Patients with schizoaffective disorder who were treated with paliperidone palmitate (as monotherapy and adjunctive therapy) experienced delayed time to relapse and reduced risk of relapse compared to patients treated with placebo.

Adult patients with binge eating disorder who were treated for 12 weeks with lisdexamfetamine dimesylate reported having 4 fewer binge days per week, and also experienced improvements in weight and triglyceride levels.

Patients in a trial of a first-in-class medication for the treatment of female sexual dysfunction reported improvement in overall sexual function, including an increase in the number of satisfying sexual events, and a concomitant decrease in distress levels associated with sexual dysfunction.

Patients with celiac disease treated with larazotide acetate experienced improvements in GI symptoms and non-GI symptoms such as headache and fatigue, as well as significant reductions in the number of symptomatic days.

Study results presented at the 2014 annual meeting of the American Psychiatric Association show that a reduced dosage of the antidepressant vilazodone is as effective as the currently approved dosage.

Study results presented at the 2014 APA annual meeting show patients treated with vortioxetine significant improvement in composite cognition scores compared to patients treated with placebo, independent of the drug's effect on their depression symptoms.

Results from a six-week study show patients with major depressive disorder treated with brexpiprazole had significantly reduced risk of akathisia and other side effects.

Though constipation as a side effect of opioid therapy is generally considered a tolerability issue that can be treated with over-the-counter laxatives, opioid-induced constipation may still lead to serious gastrointestinal complications.

Boys with Duchenne muscular dystrophy saw continued and significant clinical improvement in motor function tests after 96 weeks of administration of investigational drug eteplirsen.

Scientists studying patients with chronic pain have uncovered four specific genes that are associated with pain perception.

Study results to be presented at the 2014 AAN annual meeting show asymptomatic carotid stenosis may also contribute to impaired memory, cognitive function, and decision making.

Several studies have shown good results with Roux-en-Y gastric bypass and laparoscopic gastric banding when combined with lifestyle modifications in severely overweight patients with type 2 diabetes.

Mitigating the risk of stroke, heart failure, and death when treating patients with atrial fibrillation requires a careful consideration of patient characteristics and management options.

SAPPHIRE II trial results show sustained virologic response in 96% of treatment-experienced patients with genotype 1 hepatitis C who were treated with interferon-free, triple-drug regimen.

Study results presented at ACC.14 show treatment with PCSK9 inhibitor evolocumab significantly reduces LDL-cholesterol levels in patients with hypercholesterolemia.

Successful applications of nanotechnology in the field of immunology will enable new generations of vaccines, adjuvants, and immunomodulatory drugs that aim to improve clinical outcomes in response in a range of infectious and non-infectious diseases.